Illinois Municipal Retirement Fund Buys 2,401 Shares of United Therapeutics Corporation $UTHR

Illinois Municipal Retirement Fund grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 12.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,269 shares of the biotechnology company’s stock after buying an additional 2,401 shares during the period. Illinois Municipal Retirement Fund’s holdings in United Therapeutics were worth $13,205,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP increased its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC raised its position in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC raised its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Norges Bank bought a new stake in United Therapeutics during the fourth quarter worth about $293,418,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $644.82.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,808,586.36. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 564,743 shares of company stock worth $316,423,257. 8.60% of the stock is owned by company insiders.

United Therapeutics Stock Down 0.5%

NASDAQ UTHR opened at $529.05 on Friday. The company has a 50-day simple moving average of $552.97 and a two-hundred day simple moving average of $530.10. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market cap of $22.46 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 1.78 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the firm posted $6.63 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.